Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Macfarlane

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Journal of Alzheimer'S Disease : JAD|July 23, 2016
A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's DiseaseCharles B Malpas, Lucy Vivash, Sila Genc, et al.
The Australian and New Zealand Journal of Psychiatry|July 17, 2025
Research Letter: Delivering the new standard for psychotropic medicines on information transfers at transitions of care: A qualitative study of stakeholder prioritiesMouna Sawan, Karen Watson, Jacqueline Wesson, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 15, 2018
Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's DiseaseBarbara R Cardoso, Blaine R Roberts, Charles B Malpas, et al.
Australasian Journal on Ageing|February 26, 2026
Development of a High-Risk Medication List for Australian Residential Aged Care: A Modified Delphi StudyAmanda J Cross, Madiha Chaudhry, Darshna Goordeen, et al.
Journal of the American Medical Directors Association|July 1, 2024
Top 10 Signs and Symptoms of Psychotropic Adverse Drug Events to Monitor in Residents of Long-Term Care FacilitiesBrigid E McInerney, Amanda J Cross, Christopher P Alderman, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trialStephen Macfarlane, Timo Grimmer, Ken Teo, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Journal of Alzheimer'S Disease : JAD|July 23, 2016
A Phase IIa Randomized Control Trial of VEL015 (Sodium Selenate) in Mild-Moderate Alzheimer's DiseaseCharles B Malpas, Lucy Vivash, Sila Genc, et al.
The Australian and New Zealand Journal of Psychiatry|July 17, 2025
Research Letter: Delivering the new standard for psychotropic medicines on information transfers at transitions of care: A qualitative study of stakeholder prioritiesMouna Sawan, Karen Watson, Jacqueline Wesson, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 15, 2018
Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's DiseaseBarbara R Cardoso, Blaine R Roberts, Charles B Malpas, et al.
Australasian Journal on Ageing|February 26, 2026
Development of a High-Risk Medication List for Australian Residential Aged Care: A Modified Delphi StudyAmanda J Cross, Madiha Chaudhry, Darshna Goordeen, et al.
Journal of the American Medical Directors Association|July 1, 2024
Top 10 Signs and Symptoms of Psychotropic Adverse Drug Events to Monitor in Residents of Long-Term Care FacilitiesBrigid E McInerney, Amanda J Cross, Christopher P Alderman, et al.
The Journal of Prevention of Alzheimer'S Disease|January 12, 2025
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trialStephen Macfarlane, Timo Grimmer, Ken Teo, et al.
Pageof 5